Sales for Bio-Rad's Life Science segment were flat, but increased 9 percent on a currency-neutral basis.
Bio-Rad scientist Jennifer Berman explains how ddPCR can help detect the basic efficiency of CRISPR/Cas9 and other genome editing technologies and more.
The researchers' proof-of-concept paper published in PLOS One demonstrated a method that could lead to more haplotype analysis in genomic studies of diseases.
The suit alleges Bio-Rad fired its former general counsel for pursuing an investigation into bribery committed by the company's employees and agents in China.
Both groups are making their detailed protocols available to researchers online.
Low-pass sequencing and digital PCR analysis of cell-free circulating tumor DNA could detect metastatic disease in primary breast cancer patients months before clinical diagnosis.
On a currency-neutral basis, quarterly revenues increased about 1 percent compared to the same quarter last year.
Several early-access customers presented results from the 10X technology at the meeting.
Bio-Rad reported $598.2 million in revenues for the quarter, down from $602.6 million a year ago but surpassing the average analysts' estimate of $593.4 million.
The research may prove relevant to understanding human diversity as well as the genetic underpinning of certain CNV-related disorders.
Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.
Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.
In Science this week: research regulation and reporting requirement reform, and more.
With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.